Front & Back Matter.
- Published in:
- Oncology, 2022, v. 100, n. 10, p. 1, doi. 10.1159/000527324
- Publication type:
- Article
Works matching IS 00302414 AND DT 2022 AND VI 100 AND IP 10
Results: 6
1
2
Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
- Published in:
- Oncology, 2022, v. 100, n. 10, p. 529, doi. 10.1159/000526155
- By:
- Publication type:
- Article
3
Glucose Conferred Irinotecan Chemoresistance through Divergent Actions of Pyruvate and ATP in Cell Death and Proliferation of Colorectal Cancer.
- Published in:
- Oncology, 2022, v. 100, n. 10, p. 555, doi. 10.1159/000525977
- By:
- Publication type:
- Article
4
Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma.
- Published in:
- Oncology, 2022, v. 100, n. 10, p. 536, doi. 10.1159/000525601
- By:
- Publication type:
- Article
5
Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases.
- Published in:
- Oncology, 2022, v. 100, n. 10, p. 542, doi. 10.1159/000525082
- By:
- Publication type:
- Article
6
Retacrit®, Biosimilar of Epoetin Alfa, in Chemotherapy-Induced Anemia in Routine Practice: Impact of Iron Supplementation.
- Published in:
- Oncology, 2022, v. 100, n. 10, p. 519, doi. 10.1159/000522069
- By:
- Publication type:
- Article